CRESCENT BIOPHARMA, INC.

Crescent Biopharma, Inc. announced that its independent Compensation Committee approved the grant of options to purchase an aggregate of 65,100 ordinary shares to three non-executive employees. These equity inducement awards were made under the Company's 2025 Employment Inducement Incentive Award Plan, with an exercise price of $16.99 per share. The options, which have a 10-year term, will vest over four years, subject to continuous employment.

Crescent Biopharma, Inc. filed an amendment to its 10-Q to disclose that several key executives, including the CEO, COO, and CFO, adopted Rule 10b5-1 trading arrangements on February 25, 2026. These 'Sell-to-Cover' plans are designed to satisfy tax withholding obligations arising from the vesting of restricted and performance stock units. The amendment also includes new certifications from the principal executive and financial officers, clarifying that no financial statements were altered.

Crescent Biopharma, a clinical-stage biotechnology company, announced that its management is scheduled to present at two investor conferences in June 2026. The company will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Live webcasts of each presentation will be accessible in the Investors section of Crescent's website, with replays available for 90 days.

Crescent Biopharma, Inc. announced that its independent Compensation Committee approved the grant of options to purchase an aggregate of 16,950 ordinary shares to two non-executive employees. These equity inducement awards, approved on May 28, 2026, were material to the employees' acceptance of employment. The options have a 10-year term, an exercise price of $21.47, and vest over time, with one-fourth vesting on the first anniversary and the remainder vesting monthly thereafter.

Crescent Biopharma announced a trial in progress poster presentation for its ASCEND Phase 1/2 clinical trial of CR-001, a PD-1 x VEGF bispecific antibody, at the 2026 ASCO Annual Meeting. The global, open-label trial is evaluating CR-001 in various solid tumor types, including non-small cell lung cancer and gastrointestinal and gynecological cancers. The company anticipates initial proof-of-concept clinical data from the ASCEND trial in Q1 2027, with further data readouts for combination therapies expected in mid-2027.

Crescent Biopharma, Inc. announced that its Compensation Committee approved the grant of options to purchase an aggregate of 129,075 ordinary shares to five non-executive employees. These equity inducement awards were made under the Company's 2025 Employment Inducement Incentive Award Plan and were material to the employees' acceptance of employment. The options have a 10-year term and an exercise price of $18.52, based on the closing price on May 11, 2026. Vesting occurs over four years, with one-fourth vesting on the first anniversary and one-forty-eighth monthly thereafter, subject to continuous service.

Crescent Biopharma, a clinical-stage biotechnology company, announced that its management is scheduled to present at three investor conferences in May 2026. These include the BofA Securities 2026 Healthcare Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit. Live webcasts and replays of these presentations will be available on the company's investor relations website.

Crescent Biopharma reported a Q1 2026 net loss of $23.3 million, or $0.70 per share, on $1.0 million in revenue, up from no revenue in the prior year. The company highlighted significant progress in its clinical pipeline, with the ASCEND Phase 1/2 trial for CR-001 ongoing and two new trials for CR-001 and CR-002 on track to initiate in the second half of 2026. Multiple key clinical data readouts are anticipated to begin in Q1 2027 across its CR-001, CR-002, and CR-003 programs.

Crescent Biopharma, Inc. reported a net loss of $(23.3) million for Q1 2026, an increase from $(15.1) million in Q1 2025, as research and development expenses rose to $17.9 million. The clinical-stage biotechnology company ended the quarter with $189.2 million in cash and cash equivalents, expecting this to fund operations for at least twelve months. The company continues to incur significant operating losses and negative cash flows from operations, with an accumulated deficit of $(195.1) million.

Crescent Biopharma, Inc. reported a net loss of $(23.3) million for the first quarter of 2026, an increase from $(15.1) million in the same period last year, primarily due to higher research and development expenses. As of March 31, 2026, the company maintained a cash and cash equivalents balance of $189.2 million, which management expects to fund operations for at least the next twelve months. The company continues to be a clinical-stage biotechnology firm with no product sales revenue.